OSTEOARTHRITIS
Glucosamine sulphate, a controversial treatment for osteoarthritis
Osteoarthritis Cartilage. 2009 Apr;17(4):427-32. Epub 2008 Oct 9222 patients with osteoarthritis of the hip were randomized to receive 1500 mg of glucosamine sulphate (GS) or a placebo daily to determine which subgroups would benefit the most from GS treatment. The 24 month results from this trial indicated that GS treatment provided no improvements in WOMAC pain and function scores or joint space narrowing when compared to the placebo group. Therefore, glucosamine was no better than placebo in reducing symptoms and progression of osteoarthritis of the hip and had no effect based on type and severity of OA.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
